循环microRNA早期诊断肝细胞癌研究现状及方法学探讨

doi:10.3969/j.issn.1672-5069.2019.02.037

Abstract

Abstract: Hepatocellular carcinoma (HCC) is a malignant tumor with high morbidity and mortality. Screening and monitoring high risk population is very important. Routinely, the liver ultrasonography and serum AFP assay are the main screening methods at present, while the sensitivity and accuracy are not satisfactory. MicroRNAs(miRNAs) are closely related to the pathogenesis, metastasis and recurrence of HCC. Circulating miRNAs are important members of the serological biomarkers of HCC and have a broad prospect in the diagnosis and screening of HCC. The selection of appropriate miRNA and efficient diagnostic methods are the hot focus of related researches.

Key words: Hepatocellular carcinoma, Circulating microRNA, Molecular markers, Diagnosis

Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.

References

[1] Roberts LR,Sirlin CB,Zaiem F,et al.Imaging for the diagnosis of hepatocellular carcinoma:A systematic review and meta-analysis. Hepatology,2018,67(1):401-421.
[2] Berretta M,Cavaliere C,Alessandrini L,et al.Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma:clinical and prognostic implications. Oncotarget,2017,8(8):14192-14220.
[3] Lin S,Gregory RI.MicroRNA biogenesis pathways in cancer. Nat Rev Cancer,2015,15(6):321-333.
[4] Iwakawa HO,Tomari Y.The functions of microRNAs:mRNA decay and translational repression. Trends Cell Biol,2015,25(11):651-665.
[5] Yang Y,Lin X,Lu X,et al.Interferon-microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis. Gut,2016,65(7):1186-1201.
[6] Chai S,Ng KY,Tong M,et al.Octamer 4/microRNA-1246 signaling axis drives Wnt/beta-catenin activation in liver cancer stem cells. Hepatology,2016,64(6):2062-2076.
[7] Hou J,Lin L,Zhou W,et al.Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell,2011,19(2):232-243.
[8] Wu H,Tao J,Li X,et al.MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice. Hepatology,2017,66(6):1952-1967.
[9] Ding J,Huang S,Wu S,et al.Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol,2010,12(4):390-399.
[10] Fang T,Lyu H,Lyu G,et al.Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun,2018,9(1):191.
[11] Shen S,Lin Y,Yuan X,et al.Biomarker microRNAs for diagnosis,prognosis and treatment of hepatocellular carcinoma:a functional survey and comparison. Sci Rep,2016,6:38311.
[12] Esau C,Davis S,Murray SF,et al.MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab,2006,3(2):87-98.
[13] Kojima K,Takata A,Vadnais C,et al.MicroRNA-122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun,2011,2:338.
[14] Huang JT,Liu SM,MaH,et al. Systematic review and meta-analysis:circulating miRNAs for diagnosis of hepatocellular carcinoma. J Cell Physiol,2016,231(2):328-335.
[15] Wu H,Ng R,Chen X,et al.MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut,2016,65(11):1850-1860.
[16] Zhou J,Yu L,Gao X,et al.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol,2011,29(36):4781-4788.
[17] Tomimaru Y,Eguchi H,Nagano H,et al.Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol,2012,56(1):167-175.
[18] Dong Z,Qi R,Guo X,et al.MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation. Biochem Biophys Res Commun,2017,483(1):630-637.
[19] Dong YW,Wang R,Cai QQ,et al.Sulfatide epigenetically regulates miR-223 and promotes the migration of human hepatocellular carcinoma cells. J Hepatol,2014,60(4):792-801.
[20] Xu J,Wu C,Che X,et al.Circulating microRNAs,miR-21,miR-122,and miR-223,in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog,2011,50(2):136-142.
[21] Xie QH,He XX,Chang Y,et al.HBx gene down-regulates miR-192 expression and inhibits apoptosis of human hepatoma cell line HepG2. Chin J Hepatol,2011,19(11):857-860.
[22] Motawi TK,Shaker OG,El-Maraghy SA,et al.Serum microRNAs as potential biomarkers for early diagnosis of hepatitis C virus-related hepatocellular carcinoma in Egyptian patients. PLoS One,2015,10(9):e137706.
[23] Tan Y,Ge G,Pan T,et al.A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One,2014,9(9):e107986.
[24] Yang X,Zhang XF,Lu X,et al.MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology,2014,59(5):1874-1885.
[25] Zhang Y,Li T,Qiu Y,et al.Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. Medicine,2017,96(2):e5642.
[26] Lin XJ,Chong Y,Guo ZW,et al.A serum microRNA classifier for early detection of hepatocellular carcinoma:a multicentre,retrospective,longitudinal biomarker identification study with a nested case-control study. Lancet Oncol,2015,16(7):804-815.
[27] Zuo D,Chen L,Liu X,et al.Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based diagnosis of hepatocellular carcinoma. Tumour Biol,2016,37(5):6539-6549.
[28] Weber JA,Baxter DH,Zhang S,et al.The microRNA spectrum in 12 body fluids. Clin Chem,2010,56(11):1733-1741.
[29] Wang XW,Heegaard NH,Orum H.MicroRNAs in liver disease. Gastroenterology,2012,142(7):1431-1443.
[30] Mitchell PS,Parkin RK,Kroh EM,et al.Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A,2008,105(30):10513-10518.
[31] Marabita F,de Candia P,Torri A,et al. Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. Brief Bioinform,2016,17(2):204-212.
[32] Pepe MS,Etzioni R,Feng Z,et al.Phases of biomarker development for early detection of cancer. J Natl Cancer Inst,2001,93(14):1054-1061.
[33] Wang Z,Jensen MA,Zenklusen JC.A practical guide to the cancer genome atlas(TCGA). Methods Mol Biol,2016,1418:111-141.
[34] Ding W,Yang H,Gong S,et al.Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis. Oncol Lett,2017,13(5):3409-3414.
[35] He S,Hu XW,Wang D,et al.Accuracy of microRNAs for the diagnosis of hepatocellular carcinoma:a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol,2016,40(4):405-417.
[36] Heimbach J K,Kulik L M,Finn R S,et al.AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology,2018,67(1):358-380.
[37] European Association for The Study of The Liver. EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma. J Hepatol,2018,69(1):182-236.

Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[4]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[5]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[6]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[7]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[8]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[9]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[10]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[11]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[12]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[13]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[14]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[15]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.